ROCHESTER, Minn. — Laparoscopic sleeve gastrectomy promotes relatively rapid weight loss, reduces obesity-related health issues and improves eligibility for kidney transplantation for patients with advanced chronic kidney disease and obesity, according to new research from Mayo Clinic.
According to a study published in Mayo Clinic Proceedings, sleeve gastrectomy can improve eligibility for kidney transplantation in high-risk patients with advanced chronic kidney failure and severe obesity, who are often not considered for transplantation. The findings also show that the surgical weight-loss procedure reduced cardiovascular risks, including diabetes and hypertension.
“In earlier research, we found that conservative weight-loss approaches do not adequately result in significant weight loss in patients with advanced chronic kidney disease,” says Aleksandra Kukla, M.D., a Mayo Clinic transplant nephrologist and the study’s first author. “These new findings support the value of surgical gastrectomy for patients with advanced chronic kidney failure, stage 4-5D, to improve general health and access to kidney transplantation.”
The retrospective study involved 104 patients with advanced chronic kidney failure and obesity who were treated at Mayo Clinic between 2020 and 2023. Fifty-four underwent laparoscopic sleeve gastrectomy, the most frequently performed surgical weight-loss procedure in patients seeking kidney transplant, and 50 patients opted for a nonsurgical weight-loss approach.
Also Read: Mayo Clinic Platform launches Solutions Studio
Undergoing sleeve gastrectomy reduced the time for patients to be added to waiting lists for kidney transplantation. It also improved the likelihood of receiving a transplant, with 37% of those who underwent sleeve gastrectomy receiving a transplant within 18 months, versus 10% in the nonsurgical cohort.
Click here to join our WhatsApp channel
The risk of postsurgical complications was low, and the rate of hospitalizations and infections for patients who underwent sleeve gastrectomy was similar to the nonsurgical cohort.
Effective therapy for obesity among patients with advanced chronic kidney disease is understudied, in part because high body mass index (BMI) is often considered beneficial in patients receiving kidney dialysis. “Treatment of obesity in this population has been limited to nonsurgical options in the past,” says Tayyab Diwan, M.D., a Mayo Clinic transplant surgeon and co-author of the study.
More research is needed on the optimal timing of the surgery for kidney transplant candidates, Dr. Diwan says.
